Last reviewed · How we verify

COVAX+PPV23;COVAX+IIV4

China National Biotec Group Company Limited · FDA-approved active Biologic Quality 4/100

COVAX+PPV23;COVAX+IIV4 is a Biologic drug developed by China National Biotec Group Company Limited. It is currently FDA-approved.

At a glance

Generic nameCOVAX+PPV23;COVAX+IIV4
SponsorChina National Biotec Group Company Limited
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about COVAX+PPV23;COVAX+IIV4

What is COVAX+PPV23;COVAX+IIV4?

COVAX+PPV23;COVAX+IIV4 is a Biologic drug developed by China National Biotec Group Company Limited.

Who makes COVAX+PPV23;COVAX+IIV4?

COVAX+PPV23;COVAX+IIV4 is developed and marketed by China National Biotec Group Company Limited (see full China National Biotec Group Company Limited pipeline at /company/china-national-biotec-group-company-limited).

What development phase is COVAX+PPV23;COVAX+IIV4 in?

COVAX+PPV23;COVAX+IIV4 is FDA-approved (marketed).

Related